Eisai Co., Ltd. (TYO:4523)
4,551.00
+24.00 (0.53%)
Oct 17, 2025, 11:30 AM JST
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
73.56M JPY
Profits / Employee
4.61M JPY
Market Cap
1,276.10B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 10,917 | -150 | -1.36% |
Mar 31, 2024 | 11,067 | -9 | -0.08% |
Mar 31, 2023 | 11,076 | -246 | -2.17% |
Mar 31, 2022 | 11,322 | 85 | 0.76% |
Mar 31, 2021 | 11,237 | 239 | 2.17% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Chugai Pharmaceutical | 5,026 |
Daiichi Sankyo Company | 19,765 |
HOYA Corporation | 37,909 |
Takeda Pharmaceutical Company | 47,455 |
Otsuka Holdings | 35,338 |
Astellas Pharma | 13,643 |
Shionogi & | 4,955 |
Olympus | 29,297 |
Eisai News
- 3 days ago - LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" - Benzinga
- 8 days ago - Eisai Co., Ltd. (ESAIY) Special Call - Slideshow - Seeking Alpha
- 9 days ago - Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
- 10 days ago - Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment - Nasdaq
- 10 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - Benzinga
- 10 days ago - Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease - PRNewsWire
- 18 days ago - Eisai : LEQEMBI Approved In China For Monthly IV Maintenance Dosing In Early Alzheimer's Treatment - Nasdaq
- 22 days ago - Leqembi® approved for the treatment of early Alzheimer's disease in Australia - Benzinga